Also known as Leuprorelin · Lupron · Eligard · Leuprolide acetate
The long-acting GnRH agonist — a nonapeptide that first flares, then shuts the reproductive axis down; the workhorse of hormone-suppression medicine.
Research refreshed
Leuprolide (Lupron) is a synthetic GnRH agonist and the most widely used member of its class. Two changes to the native decapeptide — a D-leucine at position 6 and a C-terminal ethylamide replacing the terminal glycinamide — make it far more potent and degradation-resistant than gonadorelin. Given continuously as depot injections or implants, it exploits GnRH’s central paradox: sustained receptor stimulation first causes a transient hormone flare, then desensitizes the pituitary and suppresses LH, FSH, and the downstream sex steroids.
Leuprolide is the drug that made GnRH’s paradox therapeutically useful. Native GnRH must be pulsed to stimulate the pituitary; delivered continuously it does the opposite, and leuprolide is engineered to deliver exactly that steady, high-affinity signal. A D-leucine at position 6 blocks the enzymatic cleavage that clears native GnRH in minutes, and the C-terminal ethylamide raises receptor affinity — together extending its action from minutes to weeks or months in depot form.
The result is controlled, reversible chemical castration. After a brief initial flare of LH and testosterone (or estrogen), the pituitary receptor desensitizes and sex-steroid output collapses. That single effect underlies a broad set of uses: advanced prostate cancer, endometriosis and uterine fibroids, central precocious puberty, IVF protocols, and gender-affirming hormone suppression.
Leuprolide is the long-acting counterpart to gonadorelin already in this catalog: the native hormone shows the axis can be switched on or off by rhythm, while leuprolide is the manufactured, degradation-resistant analog built to hold it off. It is delivered almost entirely as sustained-release depots and implants, since its purpose depends on continuous exposure.
GnRH-receptor agonism. Continuous (non-pulsatile) exposure downregulates the receptor after an initial flare, suppressing LH / FSH and the gonadal steroids they drive.
Behind every vial of Leuprolide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Leuprolide, specifically, is brought into being.
On paper, Leuprolide is C59H84N16O12 — about 1,209.4 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Leuprolide's chain is short but unusual — it carries D-amino acids that help it resist enzymatic breakdown, but demand specialized, costlier building blocks and careful coupling on the synthesizer.
The crude mixture — Leuprolide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Leuprolide proves itself: identity confirmed by mass spectrometry against its ~1,209.4 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Leuprolide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Leuprolide is a GnRH nonapeptide analog: an N-terminal pyroglutamate, a D-leucine at position 6, and a C-terminal ethylamide in place of the native glycinamide. Solid-phase assembly is short and routine; the D-residue and the ethylamide cap are the features that must be installed correctly, and Trp/Ser byproduct control sets the purity.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Leuprolide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Leuprolide (Lupron, Eligard) is a synthetic, long-acting GnRH agonist used to suppress the reproductive hormone axis — a nonapeptide analog of GnRH with a D-leucine and a C-terminal ethylamide.
Because the GnRH receptor responds to rhythm. Continuous stimulation, after a brief initial flare, desensitizes the receptor, so LH, FSH, and sex steroids fall — the opposite of the pulsatile signal that stimulates them.
Gonadorelin is native GnRH, cleared in minutes and used in pulses to stimulate the axis. Leuprolide is a degradation-resistant analog given continuously (as depots) to shut it down.
Yes — it is approved for several conditions including prostate cancer, endometriosis, and central precocious puberty. This page is a research and educational reference, not medical advice.
The archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
ViewInsulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
ViewThe active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.